News stories about BioLineRx (NASDAQ:BLRX) have trended positive on Thursday, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioLineRx earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.1424799008097 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Investors Waiting In BioLineRx - Seeking Alpha (seekingalpha.com)
- BioLineRx Ltd. (NASDAQ:BLRX) Receives Consensus Rating of “Buy” from Brokerages (americanbankingnews.com)
- Share Performance in View for BioLineRx Ltd. (NASDAQ:BLRX) - Jonesboro Recorder (jonesbororecorder.com)
- Green Square Capital Has Increased At&T Com (T) Holding, Biolinerx Limited Ads (BLRX) SI Increased By 1.47% - Thorold News (whatsonthorold.com)
- BioLineRx: At Around $1, This Sleeper Biotech Stock Is A Strong Buy - Seeking Alpha (seekingalpha.com)
Several research firms recently issued reports on BLRX. ValuEngine raised shares of BioLineRx from a “sell” rating to a “hold” rating in a research note on Monday. Maxim Group set a $3.00 price objective on shares of BioLineRx and gave the company a “buy” rating in a research note on Monday, July 10th. Zacks Investment Research lowered shares of BioLineRx from a “buy” rating to a “sell” rating in a research note on Tuesday, June 20th. Finally, HC Wainwright set a $4.00 price objective on shares of BioLineRx and gave the company a “buy” rating in a research note on Saturday, June 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $3.18.
BioLineRx (BLRX) traded up 3.9205% on Thursday, hitting $0.9675. 902,162 shares of the stock traded hands. The firm’s 50 day moving average is $0.86 and its 200 day moving average is $0.96. The stock’s market cap is $59.77 million. BioLineRx has a 52 week low of $0.75 and a 52 week high of $1.42.
BioLineRx (NASDAQ:BLRX) last posted its earnings results on Thursday, May 25th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.03. Equities analysts anticipate that BioLineRx will post ($0.24) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “BioLineRx (NASDAQ:BLRX) Earns Daily Coverage Optimism Score of 0.28” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://stocknewstimes.com/2017/07/20/biolinerx-nasdaqblrx-earns-daily-coverage-optimism-score-of-0-28.html.
About BioLineRx
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
